In­ter­view with Phlow CEO: How soon will es­sen­tial drug man­u­fac­tur­ing come to the US?

As the vast ma­jor­i­ty of gener­ic drugs and APIs are still made over­seas, of­ten in fa­cil­i­ties where cost is a big­ger con­cern than qual­i­ty, both the Biden and Trump ad­min­is­tra­tions have pri­or­i­tized bring­ing back the man­u­fac­ture of es­sen­tial drugs and APIs to the US.

At the fore­front of this push is Phlow, which is cur­rent­ly build­ing up its US-based man­u­fac­tur­ing op­er­a­tions thanks to a four-year, $354 mil­lion con­tract from the Trump ad­min­is­tra­tion. End­points News sat down with Phlow CEO Er­ic Ed­wards via Zoom on Tues­day to dis­cuss the com­pa­ny and all things es­sen­tial med­i­cines man­u­fac­tur­ing. The in­ter­view is light­ly edit­ed for clar­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER